Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Clinical Trials › Phase 3
Explore the latest data on phase 3 clinical trials. Our analytics platform processes thousands of data points daily to deliver reliable market intelligence. Market conditions change rapidly, and staying informed is crucial for making sound decisions. This page aggregates the most relevant data points and presents them in an easily digestible format.
Historical data is available for trend analysis, allowing users to identify patterns and forecast future developments. The platform supports custom date ranges and filtering options for deeper analysis. Comparing these figures with historical averages reveals interesting patterns. The current period shows notable deviations from long-term trends in several categories, warranting closer examination.
All data on FDA News is provided for informational purposes. While we strive for accuracy, users should verify critical data points independently before making decisions.
| Trial ID | Drug | Indication | Enrollment | Status |
|---|---|---|---|---|
| NCT-2026-001 | CompA-101 | Solid tumors | 450 | Recruiting |
| NCT-2026-002 | CompB-205 | Autoimmune | 300 | Active |
| NCT-2026-003 | CompC-310 | Rare disease | 120 | Enrolling |
| NCT-2026-004 | CompD-408 | Metabolic | 600 | Active |
| NCT-2025-088 | CompE-512 | Neurological | 250 | Completed |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
